Bristol UFT/Leucovorin Approval May Await Analysis Of Uracil Contribution
Executive Summary
FDA's approval decision for Bristol's UFT for treatment of metastatic colorectal cancer may hinge on the contribution of the product's uracil component to the efficacy of the combination.
You may also be interested in...
House Committee Watching Genasense; Show Of Force During FDA Review
The House Energy & Commerce Committee is keeping a close watch on FDA's handling of the application for Aventis/Genta's Genasense
House Committee Watching Genasense; Show Of Force During FDA Review
The House Energy & Commerce Committee is keeping a close watch on FDA's handling of the application for Aventis/Genta's Genasense
Bristol To Focus On Paraplatin For Oncology Growth; UFT Review Delayed
Bristol-Myers Squibb is looking to Paraplatin (carboplatin) to lead oncology growth in the wake of a court decision opening the door to generic competition for its Taxol (paclitaxel) franchise.